Results 31 to 40 of about 218,137 (295)

Prevalence of programmed death ligand-1 in patients diagnosed with non-small cell lung cancer in Lebanon

SAGE Open Medicine, 2021
Introduction: Programmed death ligand-1 expression has been shown to be a good predictor of response to cancer therapy with checkpoint inhibitors. Its expression varies among different tumor types and among non-small cell lung cancer patients with ...
Ghina Fakhri, Reem Akel, Ibrahim Khalifeh, Hassan Chami, Adel Hajj Ali, Majd Al Assaad, Haneen Atwi, Humam Kadara, Arafat Tfayli   +8 more
doaj   +1 more source

PD-L1 Co-Stimulation Contributes to Ligand-Induced T Cell Receptor Down-Modulation on \(CD8^+\) T Cells [PDF]

, 2013
T cell receptor (TCR) down-modulation after antigen presentation is a fundamental process that regulates TCR signal transduction. Current understanding of this process is that intrinsic TCR/CD28 signal transduction leads to TCR down-modulation.
Arce, Frederick, Bennett, Clare L., Bricogne, Christopher, Collins, Mary, Escors, David, Karwacz, Katarzyna, MacDonald, Douglas   +6 more
core   +1 more source

Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?

Haematologica, 2016
Therapeutic strategies targeting the programmed cell death-ligand 1/programmed cell death-1 pathway have shown significant responses and good tolerability in solid malignancies.
Fabienne McClanahan, Thomas G. Sharp, John G. Gribben   +2 more
doaj   +1 more source

Programmed death-ligand 1 expression in surgically resected thymomas. [PDF]

Updates Surg
Abstract Thymomas are one of the most common neoplasms of the anterior mediastinum with limited therapeutic options, particularly in advanced stages. The molecular profiles of these tumors remain poorly investigated. This study aims to evaluate the expression of programmed death ligand 1 (PD-L1) in a selected cohort of intentionally curative ...
Frasca L, Sarubbi A, Longo F, Marziali V, Patirelis A, Crucitti P, Ambrogi V.   +6 more
europepmc   +5 more sources

Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study

Surgery Open Science, 2021
Background: Inhibition of the programmed death ligand 1, programmed death 1 pathway has been successfully used for treatment of multiple advanced adult cancers. However, its use in pediatric osteosarcoma is still in its infancy.
Nicholas J. Skertich, MD, Fei Chu, MD, PhD, Imad AM Tarhoni, MD, PhD, Stephen Szajek, MS, Jeffrey A. Borgia, PhD, Mary Beth Madonna, MD   +5 more
doaj   +1 more source

Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes. [PDF]

, 2016
BackgroundMalignant peripheral nerve sheath tumor (MPNST) is an aggressive sarcoma with few treatment options. Tumor immune state has not been characterized in MPNST, and is important in determining response to immune checkpoint blockade.
Bernthal, Nicholas, Chmielowski, Bartosz, Crompton, Joseph G, Dry, Sarah, Eilber, Fritz C, Federman, Noah, Jensen, Sarah, Li, Yunfeng, Nelson, Scott, Shurell, Elizabeth, Singh, Arun S, Tumeh, Paul   +11 more
core   +2 more sources

Targeting Programmed Death 1/Programmed Death Ligand 1 in Lymphoma: A Game Changer [PDF]

Journal of Oncology Practice, 2016
Programmeddeath 1 (PD-1)/programmed death ligand 1 (PD-L1) engagement is a physiologic process that inhibits the overactivation of T cells and thus serves to maintain self-tolerance and prevent autoimmunity. This mechanism is frequently hijacked by tumor cells, including lymphoma, when they aberrantly express PD-L1 (and PD-L2) proteins; however, this ...
openaire   +2 more sources

Prognostic Value of Programmed Death Ligand 1 and Programmed Death 1 Expression in Thymic Carcinoma [PDF]

Clinical Cancer Research, 2016
Abstract Purpose: The immune checkpoint of the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway is believed to play an important role in evasion of host antitumor immune surveillance in various malignancies; however, little is known about its role in thymic carcinoma.
Shintaro, Yokoyama, Hiroaki, Miyoshi, Kazutaka, Nakashima, Joji, Shimono, Toshihiro, Hashiguchi, Masahiro, Mitsuoka, Shinzo, Takamori, Yoshito, Akagi, Koichi, Ohshima   +8 more
openaire   +2 more sources

The Expression Levels and Concentrations of PD-1 and PD-L1 Proteins in Septic Patients: A Systematic Review

Diagnostics, 2022
Sepsis is a series of life-threatening organ dysfunction caused by an impaired host response to infection. A large number of molecular studies of sepsis have revealed complex interactions between infectious agents and hosts that result in heterogeneous ...
Mutiara Indah Sari, Syafruddin Ilyas
doaj   +1 more source

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. [PDF]

, 2020
PurposeTumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade.
Algazi, Alain P, Andtbacka, Robert HI, Arlauckas, Sean P, Ballesteros-Merino, Carmen, Bannavong, Donna, Bhatia, Shailender, Bifulco, Carlos, Browning, Erica, Canton, David A, Daud, Adil I, Fong, Lawrence, Fox, Bernard A, Francisco, Murray, Gargosky, Sharron, Garris, Christopher, Hermiz, Reneta, Le, Mai, Levine, Lauren P, Oglesby, Arielle, Pierce, Robert, Pittet, Mikael J, Rosenblum, Michael D, Tsai, Katy K, Twitty, Christopher G   +23 more
core   +2 more sources